Clinical Data and Duke University Collaborate on Cardio Studies
Posted on: Friday, 12 May 2006, 12:04 CDT
Clinical Data and researchers at North Carolina's Duke University have entered into a five-year research collaboration agreement focused on studying the effect of genetic variation on treatment for cardiovascular disorders.
Under terms of the agreement, Clinical Data's PGxHealth division will provide Duke University's Institute for Genome Sciences & Policy (IGSP) with non-exclusive access to its studies conducted to discover genetic variants associated with baseline lipid parameters and the response of these parameters to statins.
In return, Clinical Data receives the right to evaluate the commercial potential of any findings derived from the IGSP's studies.
Researchers at Duke IGSP are planning a series of studies to find and validate associations between genetic variants and responses to drugs used for dyslipidemia (or 'hypercholesterolemia') in a family practice setting and are also carrying out similar studies in the areas of hypertension and asthma.
"We expect that these new studies will deepen our understanding of how genetics plays a role in the efficacy of pharmaceutical products for hypercholesterolemia, potentially leading to improved efficacy and safety of treatments for these common chronic diseases," said Dr Carol Reed, senior vice president and chief medical officer of Clinical Data.
Source: Datamonitor
Related Articles
- Clinical Data's Cogenics Division to Provide Global Genotyping Solutions for Lundbeck's Clinical Studies
- Clinical Data Launches Genetic Test For Hypertrophic Cardiomyopathy (HCM)
- Clinical Data Starts Long-Term Safety Study for Vilazodone
- Nymox Announces New BPH Drug Long Term Follow-Up Study Clinical Data Presentation October 20 at American Urological Association Meeting
- Clinical Data and Algynomics to Commercialize Proprietary Genetic Pain Panel
- Clinical Data and Duke University in Pharmacogenomics Research and Commercialization Collaboration
- Clinical Data and Maple Leaf Foods in Agreement to Develop Enhanced Pork Traceability System; Genetic Test to Identify the Source of Any Pork Products Using Novel Genetic Markers
- Clinical Data Validates Genetic Predictor of Adverse Drug Reaction
- Clinical Data Achieves Validation of Genetic Biomarker for Determining Risk of Clozapine Induced Agranulocytosis
User Comments (0)

RSS Feeds